Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 4
1990 1
1991 2
1992 3
1993 3
1994 4
1995 3
1996 3
1997 4
1998 5
1999 6
2000 8
2001 7
2002 10
2003 12
2004 6
2005 17
2006 13
2007 7
2008 1
2009 3
2010 6
2011 4
2012 6
2013 4
2014 2
2015 3
2016 5
2017 4
2018 8
2019 4
2020 4
2021 5
2022 1
2023 3
2024 6
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial.
van der Wilk BJ, Eyck BM, Wijnhoven BPL, Lagarde SM, Rosman C, Noordman BJ, Valkema MJ, Bisseling TM, Coene PLO, van Det MJ, Dekker JWT, van Dieren JM, Doukas M, van Esser S, Fiets WE, Hartgrink HH, Heisterkamp J, Holster IL, Klarenbeek B, van Klaveren D, Kouw E, Kouwenhoven EA, Luyer MD, Mostert B, Nieuwenhuijzen GAP, Oostenbrug LE, Pierie JP, van Sandick JW, Sosef MN, Spaander MCW, Valkema R, van der Zaag ES, Steyerberg EW, van Lanschot JJB; SANO Study Group. van der Wilk BJ, et al. Among authors: valkema r. Lancet Oncol. 2025 Apr;26(4):425-436. doi: 10.1016/S1470-2045(25)00027-0. Epub 2025 Mar 17. Lancet Oncol. 2025. PMID: 40112851 Clinical Trial.
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB; SANO study group. Noordman BJ, et al. Among authors: valkema r. Lancet Oncol. 2018 Jul;19(7):965-974. doi: 10.1016/S1470-2045(18)30201-8. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29861116
Neoadjuvant chemoradiotherapy for resectable oesophageal cancer.
Eyck BM, van der Wilk BJ, Lagarde SM, Wijnhoven BPL, Valkema R, Spaander MCW, Nuyttens JJME, van der Gaast A, van Lanschot JJB. Eyck BM, et al. Among authors: valkema r. Best Pract Res Clin Gastroenterol. 2018 Oct-Dec;36-37:37-44. doi: 10.1016/j.bpg.2018.11.007. Epub 2018 Nov 22. Best Pract Res Clin Gastroenterol. 2018. PMID: 30551855 Review.
Potential of PSMA-targeting radioligand therapy for malignant primary and secondary brain tumours using super-selective intra-arterial administration: a single centre, open label, non-randomised prospective imaging study.
Pruis IJ, van Doormaal PJ, Balvers RK, van den Bent MJ, Harteveld AA, de Jong LC, Konijnenberg MW, Segbers M, Valkema R, Verburg FA, Smits M, Veldhuijzen van Zanten SEM. Pruis IJ, et al. Among authors: valkema r. EBioMedicine. 2024 Apr;102:105068. doi: 10.1016/j.ebiom.2024.105068. Epub 2024 Mar 22. EBioMedicine. 2024. PMID: 38518652 Free PMC article. Clinical Trial.
Neuroendocrine tumors. Peptide receptor radionuclide therapy.
Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Forrer F, et al. Among authors: valkema r. Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):111-29. doi: 10.1016/j.beem.2007.01.007. Best Pract Res Clin Endocrinol Metab. 2007. PMID: 17382268 Review.
Measuring Total Metabolic Tumor Volume from 18F-FDG PET: A Reality Check.
Boellaard R, Zwezerijnen GJC, Buvat I, Champion L, Hovhannisyan-Baghdasarian N, Orlhac F, Arens AIJ, Lobeek D, Celik F, Mitea C, Huijbregts JE, Tolboom N, de Keizer B, Valkema R, van Velden FHP, Dibbets-Schneider P, Wiegers SE, Lugtenburg PJ, Barrington SF, Zijlstra JM. Boellaard R, et al. Among authors: valkema r. J Nucl Med. 2025 May 1;66(5):802-805. doi: 10.2967/jnumed.124.269271. J Nucl Med. 2025. PMID: 40081961
Peptide-receptor radionuclide therapy for endocrine tumors.
van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. van Essen M, et al. Among authors: valkema r. Nat Rev Endocrinol. 2009 Jul;5(7):382-93. doi: 10.1038/nrendo.2009.105. Epub 2009 Jun 2. Nat Rev Endocrinol. 2009. PMID: 19488074 Review.
Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP. de Herder WW, et al. Among authors: valkema r. J Endocrinol Invest. 2005;28(11 Suppl International):132-6. J Endocrinol Invest. 2005. PMID: 16625862 Review.
Peptide receptor radionuclide therapy.
Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Krenning EP, et al. Among authors: valkema r. Ann N Y Acad Sci. 2004 Apr;1014:234-45. doi: 10.1196/annals.1294.026. Ann N Y Acad Sci. 2004. PMID: 15153440 Review.
Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.
van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. van der Wilk BJ, et al. Among authors: valkema r. Dig Surg. 2019;36(6):462-469. doi: 10.1159/000493435. Epub 2018 Sep 18. Dig Surg. 2019. PMID: 30227434 Free PMC article. Review.
173 results